Adamis Pharmaceuticals Corp. Daily Stock Analysis

Daily Stock Analysis, ADMP, Adamis Pharmaceuticals Corp, priceseries

Adamis Pharmaceuticals Corp. Daily Stock Analysis
Stock Information
Open
0.59
Close
0.60
High
0.63
Low
0.59
Previous Close
0.63
Daily Price Gain
-0.03
YTD High
0.85
YTD High Date
Jan 10, 2022
YTD Low
0.52
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.02
YTD Gain
-3.23%
52 Week High
1.48
52 Week High Date
Oct 18, 2021
52 Week Low
0.52
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-0.32
52 Week Gain
-34.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
3.15
Feb 22. 2017
3.32
10 Trading Days
5.44%
Link
LONG
Mar 6. 2017
3.75
Mar 21. 2017
4.34
11 Trading Days
15.79%
Link
LONG
Jun 15. 2017
5.75
Jun 16. 2017
6.10
1 Trading Days
6.09%
Link
LONG
Aug 21. 2017
4.85
Sep 11. 2017
5.23
14 Trading Days
7.75%
Link
LONG
Mar 5. 2018
3.40
Mar 14. 2018
3.61
7 Trading Days
6.25%
Link
LONG
May 15. 2018
4.05
May 30. 2018
4.29
10 Trading Days
5.85%
Link
LONG
Sep 20. 2018
3.05
Sep 28. 2018
3.40
6 Trading Days
11.45%
Link
LONG
Jan 15. 2019
2.51
Feb 7. 2019
2.97
16 Trading Days
18.22%
Link
LONG
Jul 10. 2020
0.58
Aug 7. 2020
1.19
20 Trading Days
106.60%
Link
LONG
Jan 4. 2021
0.54
Jan 29. 2021
1.14
18 Trading Days
110.53%
Link
LONG
Feb 5. 2021
1.22
Feb 18. 2021
1.37
8 Trading Days
12.67%
Link
Company Information
Stock Symbol
ADMP
Exchange
NasdaqCM
Company URL
http://www.adamispharmaceuticals.com
Company Phone
(858) 997-2400
CEO
Dennis J. Carlo
Headquarters
California
Business Address
11455 EL CAMINO REAL, SUITE 310, SAN DIEGO, CA 92130
Sector
-
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0000887247
About

Adamis Pharmaceuticals Corp. is a pharmaceutical company engages in the provision of medical development. Its activities include the combination of specialty pharmaceuticals and biotechnology to produce medicines for patients, and physicians. It focuses on products such as inhaler technology in the field of allergy and respiratory diseases. The company was founded on April 1, 2009 and is headquartered in San Diego, CA.

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. Its specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-2000 for the treatment of bronchospasms. The company also has various biotechnology product candidates and technologies, including therapeutic vaccine and cancer product candidates that comprise TeloB-VAX (vaccine), APC-100, APC-200, and APC-300, which are under development for the treatment of prostate cancer. In addition, it operates a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals, and surgery centers in the United States. The company is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading